logo
  Join        Login             Stock Quote

Merrimack Pharma (MACK) Starts Advanced Solid Tumors Study

 December 12, 2012 12:37 PM


(By Balaseshan) Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) said it has initiated phase 1 clinical study of MM-141 and enrolled its first patient for the treatment of advanced solid tumors.

Merrimack is currently pursuing clinical indications where PI3K/AKT/mTOR inhibitors have demonstrated signs of clinical activity and where IGF-1R and ErbB3 signaling has been shown to play a role in existing or acquired resistance.

The phase 1 study will assess the safety of MM-141 as a monotherapy and in combination with everolimus and docetaxel and to determine the recommended Phase 2 dose.

Four sites are currently expected to participate in this trial focusing on patients with advanced solid tumors that have progressed following standard of care therapy. The first patient was dosed at Georgia Cancer Specialists in Atlanta.

MM-141 is a fully human tetravalent antibody designed to target signaling of the P13K/AKT/mTOR pathway driven through IGF-1R and ErbB3 (HER3). It is Merrimack's sixth oncology candidate to enter clinical development.

PI3K/AKT/mTOR signaling is often activated in cancers in response to stress induced by chemotherapies or targeted anti-cancer medicines. It is believed to play a significant role in promoting tumor cell survival.

"Cancer therapies focused on P13K/AKT/mTOR have not been effective because they have struggled to address the underlying redundancies and adaptations in signaling that drive cancer cell survival. Merrimack has engineered MM-141 to focus specifically on key pathways of IGF-1R and ErbB3 signaling to address this issue," said Ulrik Nielsen, Co-Founder and Chief Scientific Officer of Merrimack.

MACK is trading up 1.52% at $6.56 on Wednesday. The stock has been trading between $5.66 and $11.11 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageChart Says This Retailer's Comeback Isn't Finished

One of the surprises, at least on the surface, of the market's recent swoon was the outperformance of read on...

article imageETF Performance Review: Major Asset Classes | 19 Dec 2014

It’s all about real estate investment trusts (REITs) these days when it comes to bullish performance among read on...

article imageOil and Global Stock Markets Rebounding Sharply

So far so good on our expectation of a 4 to 5% pullback and then a resumption of the bull read on...

article imageGrading the FOMC

Love its members or loathe them, you have to admire the gradual impact the policy-making committee has had read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center

Related Articles:

Recent Articles by Balaseshan
More Articles on: Medical



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.